Antiangiogenesis Research Is Booming, As Questions and Studies Proliferate

Antiangiogenesis research is booming, as questions and studies proliferate.

I n a recent analysis of a large observational study, bevacizumab (Avastin), an inhibitor of angiogenesis, was associated with favorable survival rates in patients whose colorectal cancer had already progressed. Those taking bevacizumab with chemotherapy had a median overall survival of 32 months, compared with 20 months for those who did not receive bevacizumab beyond first-line therapy. The d...

More Enduring Questions in Cognitive IS Research

In the April 2012 issue of the Journal of the Association for Information Systems, Michael Davern, Teresa Shaft, and Dov Te’eni published an article titled “Cognition Matters: Enduring Questions in IS Research”. Their paper reviewed much of the history of cognitive research in the IS discipline, especially that related to humancomputer interaction and decision support systems. While we believe ...

From antiangiogenesis to hypoxia: current research and future directions

Angiogenesis has long been recognized as an essential element in tumor growth. Since the conception of antiangiogenesis for cancer therapeutics, great strides have been made in understanding the molecular biology underlying angiogenesis, both in cancer and in physiology. By capitalizing on these advancements through bench-to-bedside research, potent antiangiogenic agents have been developed and...

Forty Data Communications Research Questions Forty Data Communications Research Questions

About ten years ago, Bob Lucky asked me for a list of open research questions in networking. I didn’t have a ready list and reacted it would be good to have one. This essay is my (long-belated) reply.

To proliferate, not to proliferate or to die. The liver itself decides as needed.